London, UK, and Copenhagen, Denmark: 16 June 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that a review of data supporting the development of AS1413 (amonafide L-malate; formerly Xanafide) in secondary acute myeloid leukaemia (AML) was presented yesterday at the European Hematology Association (EHA) meeting in Copenhagen, Denmark. The presentation was made by Robert L. Capizzi, M.D., Xanthus' Chief Medical Officer, and is available on Antisoma's website at http://www.antisoma.com/asm/products/as1413
